CLINICAL BENEFIT OF LENALIDOMIDE TREATMENT FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME WITH DEL(5Q) BEFORE TRANSFUSION DEPENDENCE

被引：0
|
作者：
Oliva, E. [1 ]
Lauseker, M. [2 ]
Spiriti, M. A. Aloe [3 ]
Poloni, A. [4 ]
Cortelezzi, A. [5 ]
Palumbo, G. [6 ]
Balleari, E. [7 ]
Sanpaolo, G. [8 ]
Volpe, A. [9 ]
Ricco, A. [10 ]
Ronco, F. [1 ]
Alati, C. [1 ]
Santacaterina, I. [1 ]
Kuendgen, A. [11 ]
Germing, U. [11 ]
Latagliata, R. [12 ]
机构：
[1] Azienda Osped BMM, Reggio Di Calabria, Italy
[2] Univ Munich, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany
[3] Univ Roma La Sapienza, Dipartimento Med Clin & Mol, I-00185 Rome, Italy
[4] Univ Politecn Marche, Ancona, Italy
[5] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[6] Azienda Osped Univ Policlin Vittorio Emanuele, Catania, Italy
[7] Osped San Martino Genova, Hematol Unit, Genoa, Italy
[8] Osped Casa Sollievo della Sofferenza, Hematol Div, San Giovanni Rotondo, Italy
[9] Azienda Osped San G Moscati, Avellino, Italy
[10] Univ Bari, Bari, Italy
[11] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[12] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S1331
引用
收藏
页码：517 / 517
页数：1
相关论文
共 50 条
  • [1] Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
    Oliva, Esther N.
    Lauseker, Michael
    Spiriti, Maria Antonietta Aloe
    Poloni, Antonella
    Cortelezzi, Agostino
    Palumbo, Giuseppe A.
    Balleari, Enrico
    Sanpaolo, Grazia
    Volpe, Antonio
    Ricco, Alessandra
    Ronco, Francesca
    Alati, Caterina
    D'Errigo, Maria Grazia
    Santacaterina, Irene
    Kuendgen, Andrea
    Germing, Ulrich
    Latagliata, Roberto
    CANCER MEDICINE, 2015, 4 (12): : 1789 - 1797
  • [2] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Cogle, Christopher
    Tinsley, Sara
    Sallman, David
    Lancet, Jeffrey E.
    Lis, Alan F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
  • [3] BONE MARROW CYTOKINE CHANGES DURING TREATMENT WITH LENALIDOMIDE IN LOW AND INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITH DEL(5Q)
    Oliva, N.
    Ronco, F.
    Cuzzola, M.
    Alimena, G.
    Morabito, F.
    Spiriti, M. A. Aloe
    Galimberti, S.
    Cortelezzi, A.
    Specchia, G.
    Poloni, A.
    Ghio, R.
    Breccia, M.
    Finelli, C.
    Iacopino, P.
    D'Errigo, Mg
    Lagana, C.
    Latagliata, R.
    Nobile, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 381 - 381
  • [4] Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q)
    Oliva, Esther Natalie
    Nobile, Francesco
    Ronco, Francesca
    Alati, Caterina
    Morabito, Fortunato
    Poloni, Antonella
    Cortelezzi, Agostino
    Spiriti, Maria Antonietta Aloe
    Ricco, Alessandra
    Volpe, Antonio
    Balleari, Enrico
    Sanpaolo, Grazia
    Breccia, Massimo
    Clissa, Cristina
    Alimena, Giuliana
    Latagliata, Roberto
    BLOOD, 2010, 116 (21) : 1205 - 1206
  • [5] A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Lee, Ji-Hyun
    Hillgruber, Nancy
    Tinsley, Sara
    Lancet, Jeffrey E.
    List, Alan
    BLOOD, 2013, 122 (21)
  • [6] Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure
    Giagounidis, Aristoteles
    Goehring, Gudrun
    Haase, Sabine
    Aul, Carlo
    Schlegelberger, Brigitte
    Kuendgen, Andrea
    Herbst, Regina
    Ehninger, Gerhard
    Platzbecker, Uwe
    BLOOD, 2009, 114 (22) : 1464 - 1465
  • [7] Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion
    Yang, Yan
    Gao, Sujun
    Fan, Hongqiong
    Lin, Hai
    Li, Wei
    Wang, Juan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6 (03) : 803 - 807
  • [8] MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE
    Gritsaev, S. V.
    Martinkevitch, I. S.
    Petrova, E. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (02): : 3 - 10
  • [9] Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study
    Poloni, Antonella
    Raaschou-Jensen, Klas
    Mohedo, Francisca Hernandez
    Paolini, Stefania
    Oliva, Esther Natalie
    Buccisano, Francesco
    Vasconcelos, Alberto
    Kim, Iris
    Makwana, Aidan
    Bernasconi, David
    Rosettani, Barbara
    Prebet, Thomas
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (03): : e131 - e142
  • [10] ANALYSIS OF SHORT-TERM EFFICACY OF LENALIDOMIDE IN PATIENTS WITH INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME WITHOUT 5Q DELETION
    Yang, Y.
    HAEMATOLOGICA, 2012, 97 : 582 - 582
12345